Novo Nordisk ramps up legal case against compounding pharmacies selling 'misbranded' semaglutide
Novo Nordisk is taking another Florida pharmacy to court after allegedly finding impurities in its compounded drugs marketed as semaglutide, including one sample that was 33% impure, according to court documents.
It’s the latest in a string of lawsuits filed by Novo and its rival Eli Lilly in an attempt to stop wellness centers and compounding pharmacies from what they believe is improper marketing of the popular diabetes and weight loss products.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.